Catalyst Pharmaceuticals Inc (CPRX) Company Profile & Statistics

Catalyst Pharmaceuticals Inc
CPRX
(Nasdaq - US)
Closed
21.12
-0.03 (-0.14%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
21.13
High
21.16
Low
20.87

About Catalyst Pharmaceuticals Inc

CEO

Richard J. Daly

Headquarters

355 alhambra circle,suite 801

coral gables, fl 33134, united states

Auditor

GRANT THORNTON LLP

Employees

167

Share Holders

Website

www.catalystpharma.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.

Catalyst Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	2.52B
Enterprise Value	2.08B
Enterprise Value/EBITDA (ttm)	9.82
Price to Earnings Ratio (ttm)	11.56
Price to Book (mrq)	3.84
Price to Sales (ttm)	5.54
Price to Cash (ytd)	10.40

Profitability

Gross Margin (ttm)	86.36%
Operating Margin (ttm)	49.13%
Profit Margin (ttm)	30.62%
Return on Equity (ttm)	40.79%
Return on Invested Capital (ttm)	26.47%
Return on Assets (ttm)	34.87%

Income Statement

Revenue (ttm)	460.48M
Revenue Per Share (ttm)	3.86
Gross Profit (ttm)	397.47M
EBITDA (ttm)³	211.43M
Net Income Avi to Common (ttm)	142.80M
Diluted EPS (ttm)	1.18

Share Statistics

Beta (5Y Monthly)	0.75
52-Week Change	54.05%
S&P500 52-Week Change	31.08%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	119.27M
Dividend Yield	0.00%
Float ⁴	106.15M
% Held by Insiders	11.00%
% Held by Institutions	79.22%

Balance Sheet

Total Cash (mrq)	442.33M
Total Cash Per Share (mrq)	3.71
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	5.11%
Quick Ratio (mrq)	4.92%
Book Value Per Share (mrq)	5.54

Cash Flow

Operating Cash Flow Per Share (ytd)	1.35
Free Cash Flow (ytd)	168.46M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Catalyst Pharmaceuticals Inc

Trade With A Regulated Broker